Log InSign Up
MissionModelBlogPricingVitaeLeaderboardLibrary

ALNY

StatementStatement RatioRatio
NewsNews
Yahoo Finance Google Finance Market Beat Bar Chart

Alnylam Pharmaceuticals Inc. Common Stock (NASDAQ:ALNY)

Real-time price： | Most recent change：0.00%

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year.....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 18 July 2026

Blog+More

Many U.S. large public corporations spend their tax cuts on new dividend payout and share buyback.

Jacob Miramar

2018-05-23 09:41:00 Wednesday ET

Many U.S. large public corporations spend their tax cuts on new dividend payout and share buyback.

Many U.S. large public corporations spend their tax cuts on new dividend payout and share buyback but not on new job creation and R&D innovation. These

+See More

Fed Chair Jerome Powell increases the neutral interest rate to a range of 1.5% to 1.75% in his debut press conference.

Chanel Holden

2018-03-21 06:32:00 Wednesday ET

Fed Chair Jerome Powell increases the neutral interest rate to a range of 1.5% to 1.75% in his debut press conference.

Fed Chair Jerome Powell increases the neutral interest rate to a range of 1.5% to 1.75% in his debut post-FOMC press conference. The Federal Reserve raises

+See More

World politics, economics, and new ideas from the Psychology of Money written by Morgan Housel

Daphne Basel

2023-10-19 08:26:00 Thursday ET

World politics, economics, and new ideas from the Psychology of Money written by Morgan Housel

World politics, economics, and new ideas from the Psychology of Money written by Morgan Housel We would like to provide both economic and non-economic th

+See More

Platform enterprises leverage network effects, scale economies, and information cascades to boost exponential user growth.

Fiona Sydney

2020-05-28 15:37:00 Thursday ET

Platform enterprises leverage network effects, scale economies, and information cascades to boost exponential user growth.

Platform enterprises leverage network effects, scale economies, and information cascades to boost exponential business growth. Laure Reillier and Benoit

+See More

The Trump administration blames China for egregious currency misalignment.

Olivia London

2018-10-17 12:33:00 Wednesday ET

The Trump administration blames China for egregious currency misalignment.

The Trump administration blames China for egregious currency misalignment, but this criticism cannot confirm *currency manipulation* on the part of the Chin

+See More

New York Fed CEO John Williams sees no need to raise the interest rate unless economic growth or inflation rises to a high gear.

Joseph Corr

2019-02-28 12:39:00 Thursday ET

New York Fed CEO John Williams sees no need to raise the interest rate unless economic growth or inflation rises to a high gear.

New York Fed CEO John Williams sees no need to raise the interest rate unless economic growth or inflation rises to a high gear. After raising the interest

+See More